January 3, 2005 - Subject recipient of two surgically-inflicted wounds to nose occasioned by removal of benign growths. Subject volunteers to try topical CGP (Cellerity) to investigate possible differential wound healing: one wound treated with Cellerity and the other receiving standard treatment.

January 4, 2005 - 24 hrs. post surgery: both wound sites are initially inflamed and moist. Patient's left side wound is deeper than front wound. Worst of two sites (L.) is selected for CGP treatment. Subject instructed to apply issued 7.5% CGP topical formulation to L. side only, 2x daily. Per physician, Neosporin applied to both sites for one week. Subject instructed to return to AkPharma laboratory for weekly observations. (Figure 1)

January 11, 2005 - Day 7 treatment phase. Both wounds still red; both dryer. Treated wound appears less deep than on January 4 and margins between wound and undamaged skin blending. No significant difference in untreated wound depth, although inflammation marginally lessened. (Figure 2)

January 20, 2005 - Day 16 treatment phase. Treated site healing appears significantly advanced, with epidermal skin recolonized over excised area - note only fading pale pinkish color of healing skin. Untreated wound: red scab. Subject requests permission to treat other wound with Cellerity - Instructed not do this. (Figure 3)

February 3, 2005 - Day 30 treatment phase. Treated site - healed-fully recolonized with epidermal skin- damage almost unnoticeable; demonstrates enhanced lateral healing/ recolonization of stratum corneum. This site has not formed scab to date. Untreated wound - open with small inner scab + red encirclement. Subject reports untreated wound has scabbed-over 3 times. (Figure 4)

February 10, 2005 - Day 37 treatment phase. Treated site completely healed. Untreated wound still presents with small inner scab + red encirclement. (Figure 5)

February 24, 2005 - Day 51 treatment phase. Treated site completely healed. Untreated wound still presents small inner scab + pink encirclement. (Figure 6)